SANUWAVE Health, Inc.
Datakwaliteit: 100%
SNWV
Nasdaq
Manufacturing
Measuring & Analyzing Instruments
€ 16,84
▼
€ 1,32
(-7,27%)
Marktkapitalisatie: 155,56 M
Prijs
€ 18,10
Marktkapitalisatie
155,56 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Revenue grew 35,65% annually over 5 years — strong growth
Net margin of 26,82% shows strong profitability
Generating 1,93 M in free cash flow
P/E of 13,17 — trading at a low valuation
Capital efficient — spends only 4,41% of revenue on capex
ROIC of 382,49% — excellent capital efficiency
Groei
Revenue Growth (5Y)
35,65%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)34,98%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC382,49%
Net Margin26,82%
Op. Margin11,23%
Veiligheid
Debt / Equity
N/A
Current Ratio1,16
Interest Coverage0,88
Waardering
PE (TTM|2027)
13,17 | 18,76
Boven sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDA28,59
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 13,2 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,3 |
| Net Margin % | 26,8 | -41,5 |
| Rev Growth 5Y % | 35,7 | 1,8 |
| D/E | — | 0,3 |
Koersdoel Analisten
2 analisten
Buy
Huidig
€ 16,84
Koersdoel
€ 43,50
€ 40,00
€ 43,50
€ 47,00
Vooruitzicht
Forward K/W
17,45
Forward WPA
€ 0,97
WPA Groei (sch.)
+141,3%
Omzet Sch.
65,34 M
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
€ 0,97
€ 0,37 – € 1,56
|
65,34 M | 2 |
| FY2026 |
€ 0,40
-€ 0,06 – € 0,86
|
52,07 M | 2 |
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| 2026 Q2 |
€ 0,05
-€ 0,03 – € 0,13
|
11,51 M | 2 |
| 2026 Q1 |
-€ 0,04
-€ 0,12 – € 0,05
|
9,84 M | 2 |
Winstverassingen
Laatste 4 kwartalen
| Kwartaal | Geschat WPA | Werkelijk WPA | Verrassing |
|---|---|---|---|
| Q42025 | € 0,17 | € 0,03 | -82,4% |
| Q32025 | € 0,32 | € 0,46 | +43,8% |
| Q22025 | -€ 0,09 | € 0,01 | +111,1% |
| Q12025 | N/A | -€ 0,66 | — |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 34,98% | Revenue Growth (3Y) | 46,95% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 35,65% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 44,05 M | Net Income (TTM) | 11,81 M |
| ROE | N/A | ROA | 34,42% |
| Gross Margin | 77,11% | Operating Margin | 11,23% |
| Net Margin | 26,82% | Free Cash Flow (TTM) | 1,93 M |
| ROIC | 382,49% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1,16 |
| Interest Coverage | 0,88 | Asset Turnover | 1,28 |
| Working Capital | 3,06 M | Tangible Book Value | -13,39 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 13,17 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 3,53 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 28,59 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 1,24% | ||
| Market Cap | 155,56 M | Enterprise Value | 169,24 M |
| Per Share | |||
| EPS (Diluted TTM) | 0,41 | Revenue / Share | 5,13 |
| FCF / Share | 0,23 | OCF / Share | 0,45 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 4,41% | FCF Conversion | 16,37% |
| SBC-Adj. FCF | -1,58 M | Growth Momentum | -0,67 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 44,05 M | 32,63 M | 20,40 M | 16,74 M | 13,01 M |
| Net Income | 11,81 M | -31,37 M | -25,81 M | -10,29 M | -27,26 M |
| EPS (Diluted) | 0,41 | -7,03 | -0,03 | -0,02 | -0,05 |
| Gross Profit | 33,97 M | 24,55 M | 14,36 M | 12,41 M | 8,02 M |
| Operating Income | 4,95 M | 5,42 M | -540.000,0 | -8,95 M | -14,14 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 1,35 M | 673.000,0 | 579.000,0 | 567.000,0 | 1,10 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 974.000,0 | 1,15 M | 1,03 M | 952.000,0 | 532.000,0 |
| Interest Expense | 5,64 M | — | — | 12,77 M | 6,88 M |
| Income Tax | 86.000,0 | 27.000,0 | 4.000,0 | 2.000,0 | 28.000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 37,34 M | 30,12 M | 22,42 M | 19,87 M | 18,62 M |
| Total Liabilities | 35,72 M | 42,84 M | 65,59 M | 60,88 M | 57,58 M |
| Shareholders' Equity | 1,62 M | -12,72 M | -43,18 M | -41,01 M | -38,96 M |
| Total Debt | 21,89 M | — | — | 1,48 M | 26,26 M |
| Cash & Equivalents | 11,96 M | 10,24 M | 1,80 M | 1,15 M | 619.000,0 |
| Current Assets | 24,63 M | 18,40 M | 9,78 M | 6,62 M | 4,40 M |
| Current Liabilities | 17,85 M | 42,35 M | 64,76 M | 60,19 M | 56,26 M |
{"event":"ticker_viewed","properties":{"ticker":"SNWV","listing_kind":"stock","pathname":"/stocks/snwv","exchange":"Nasdaq","country":"US"}}